NAMS Projected Dividend Yield
Shs/NewAmsterdam Pharma Company N V ( NASDAQ : NAMS )NewAmsterdam Pharma is a clinical-stage biopharmaceutical company. Co. is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. 21 YEAR PERFORMANCE RESULTS |
NAMS Dividend History Detail NAMS Dividend News NAMS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |